Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex.
Rationally designed combinations of rifampicin (RAMP) and thiacetazone plus isonicotinic acid hydrazide and/or ethambutol are highly effective in the treatment of patients (including HIV-positive) infected with multiply resistant mycobacteria of the Mycobacterium avium complex (MAC). Clinical results are very promising. The high efficacy of these combinations is due to the synergistic potentiation of single-drug activities. As soon as rifabutin is marketed, it should replace RAMP in the combination treatment of patients with highly RAMP-resistant MAC bacteria.
Seydel
J K
JK
Borstel Research Institute, FRG.
Schaper
K J
KJ
Rüsch-Gerdes
S
S
D002851:Chromatography, High Pressure Liquid; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000494:pharmacology*; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D012293:Rifampin / Q000097:blood / Q000494:pharmacology*; D013828:Thioacetazone / Q000097:blood / Q000494:pharmacology*
D004977:Ethambutol; D013828:Thioacetazone; D007538:Isoniazid; D012293:Rifampin